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over the follow-up period. After matching, there was no
signiﬁcant difference in health services utilization between
drug groups. However, risperidone subjects had signiﬁ-
cantly lower pharmacy costs (<.0001) and total costs (p
= 0.0181) compared to olanzapine subjects. Subjects with
affective disorders had total costs that were signiﬁcantly
higher compared to subjects with schizophrenia or child-
hood disorders. CONCLUSIONS: Studies comparing
cost and utilization among atypical antipsychotics should
consider the host of factors that may inﬂuence receipt or
regiment of care such as diagnostic condition, duration
of therapy and dosing.
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OBJECTIVE: Factors inﬂuencing atypical antipsychotic
selection include physician preference, and patient char-
acteristics. Studies comparing risperidone, quetiapine,
olanzapine and ziprasidone resulted in inconclusive evi-
dence suggesting superiority of one agent over another.
Amidst concerns over increasing drug expenditures, cost
has become a major issue in the drug sector. Therefore,
the purpose of this study is to model the potential annual
cost savings that may occur as a result of shifting utiliza-
tion from risperidone, quetiapine, and olanzapine to
ziprasidone within the Wisconsin Medicaid population.
METHODS: Retrospective review of Wisconsin Medic-
aid paid prescription claims data from January 1, 2001
to December 31, 2001. Utilization of schizophrenic doses
of risperidone, quetiapine, olanzapine, and ziprasidone
were extracted for this analysis. The main outcomes cal-
culated were cost per unit, mean cost per claim, and total
yearly expenditure per drug. To test the robustness of the
analysis, we modeled the total savings by estimating a
10%, 20% and 50% shift of risperidone, quetiapine and
olanzapine utilization to ziprasidone. RESULTS: Total
number of claims in 2001 for risperidone, quetiapine,
olanzapine and ziprasidone were 41,408, 36,722, 48,647,
and 9,288, respectively. The corresponding annual 
total dollar payouts were $8,705,264, $7,271,390,
$17,081,012, and $1,729,874 respectively. The cost per
claim for ziprasidone ($186.25) was signiﬁcantly lower
than olanzapine ($351.12), quetiapine ($198.01), and
risperidone ($210.23). A 50% shift to ziprasidone would
result in a total cost savings of $4,722,833,70 annually.
CONCLUSION: This analysis suggests that there is a
potential for substantial cost savings within the 
Wisconsin state Medicaid system that would occur as a
results of shifting utilization from other atypical antipsy-
chotics to ziprasidone.
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OBJECTIVES: The economic burden of depression was
estimated at approximately $44 billion in 1990. A sub-
sequent study reﬁned the estimation of the morbidity
costs associated with depressive disorders and revised this
ﬁgure to $53 billion. The objective of this study is 
to provide a 10-year update of the economic burden 
of depression using the same reﬁned methodology.
METHODS: Using a human capital approach we devel-
oped prevalence-based estimates of 3 major cost cate-
gories: 1) direct costs, 2) mortality costs arising from
depression-related suicides, and (3) morbidity costs 
associated with workplace depression. Estimates were
updated to reﬂect 2000 values, using the most current epi-
demiological data for prevalence rates and publicly avail-
able cost data by condition. RESULTS: We estimate that
the total economic burden of depression in 2000 was
$81.5 billion. Of this total, $26.1 billion—32%—are
direct medical costs, $5.4 billion—7%—are mortality
costs, and $49.9 billion—61%—are morbidity costs.
Work absenteeism resulted in $34.5 billion—42% of total
costs, while work cutback costs were $15.4 billion—19%
of total costs. CONCLUSIONS: The economic burden of
depression was $81.5 billion in 2000. Morbidity gener-
ated the largest portion, 61%, of these costs. Future
research investigations will incorporate additional costs
associated with depressive disorders, including the excess
costs of treating comorbid illnesses and the cost burden
of depressed individuals’ family members.
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OBJECTIVES: Depression is a major public health issue
in the United States. It is associated with high morbidity
and mortality. Hence it is important to evaluate its eco-
nomic impact on the U.S. health care system. Information
about the economic burden of depression will help 
in effective utilization and allocation of healthcare
resources. The main outcome measure of this study was
the economic burden of depression in a patient popula-
tion of 703 with a primary diagnosis of depression.
METHODS: A secondary database analysis was con-
ducted using the Medical Expenditure Panel Survey, 1999
(MEPS 99). Patients with primary diagnoses of depres-
sion were identiﬁed using International Classiﬁcation of
Diseases, 9th revision, Clinical Modiﬁcation (ICD 9 CM).
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The economic burden of the disease in this study was
deﬁned as the sum of direct costs and indirect costs.
Direct costs include physician, non-physician, outpatient,
inpatient, emergency room, and home healthcare ex-
penses. Indirect costs include working days missed 
and wages lost due to illness. RESULTS: The direct 
cost for 703 patients diagnosed with depression was
US$4,973,140 and the indirect cost was US$183,855.
The economic burden was US$5,156,995 and the aver-
age cost was US$7,336/patient/year. The average co-
morbidity for the sample of 703 patients was 4.8, with a
minimum of one and maximum of 19. CONCLUSIONS:
The average cost of depression of US$7336/patient/year
is three-fold higher (after adjusting for inﬂation) than the
1990 estimate of US$1600/patient/year as obtained from
the National Institute of Mental Health report. Thus,
there is signiﬁcant economic burden of depression on the
US healthcare system. Regulating prescription costs along
with increased patient awareness may help in reducing the
economic burden of depression.
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OBJECTIVES: This study compared the costs in claims
associated with ﬁbromyalgia plus depression, ﬁbromyal-
gia alone, and depression alone. METHODS: Using
administrative claims data from a national Fortune 100
manufacturer, 3 mutually exclusive cohorts and an overall
beneﬁciary cohort were deﬁned based on diagnostic
claims: ﬁbromyalgia-only, depression-only, ﬁbromyalgia
plus depression, and a random sample comprising 10%
of the employer’s overall beneﬁciary sample. The cohorts
were compared for demographics, comorbid conditions,
health care resources used, medication use by therapeu-
tic class, and mean direct costs and imputed indirect 
costs. RESULTS: Mean annual costs per patient to the
employer were $5,163 for ﬁbromyalgia-only, $8,073 for
depression-only, $11,899 for ﬁbromyalgia plus depres-
sion, and $2,486 for patients in the overall sample. Mean
incremental employer costs (above overall sample pay-
ments) per patient for those with ﬁbromyalgia plus
depression were a cost addition of $1,149 when com-
pared with the sum of the incremental costs for those with
ﬁbromyalgia-only and depression-only ((11,899 - 2,486)
- (5,163 - 2,486) + (8,073 - 2,486)). For every dollar
spent on ﬁbromyalgia healthcare costs for employees
(medical care plus prescriptions), the employer spent $57
to $143 on additional direct and indirect costs. CON-
CLUSIONS: Patients with both ﬁbromyalgia and depres-
sion claims are high users of the health care system.
Although data are limited to an insured population, they
concur with previous literature establishing relationships
between depression and painful conditions. When
ﬁbromyalgia and depression co-occur there is more than
additive relationship between the incremental costs versus
single syndrome cohorts. Improved management of these
patients could result in reduced patient, physician and
employer burdens.
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OBJECTIVES: Although much information has been
published on St. John’s Wort, the question of cost-
effectiveness remains to be addressed. The objective of
this study was to determine the cost-effectiveness of St.
John’s Wort compared to ﬂuoxetine from a third party
perspective for the treatment of mild to moderate depres-
sion. METHODS: An expert panel of two psychiatrists,
one pharmacist, and three primary care physicians was
surveyed to establish a decision analytic model of depres-
sion management in the outpatient setting over a treat-
ment period of one year. Treatment with ﬂuoxetine 20mg
daily was compared to treatment with St. John’s Wort
300mg thrice daily for patients diagnosed with mild to
moderate depression. Probabilities of the various out-
comes included in the decision tree were obtained from a
Medline search as well as the survey of the expert panel.
Direct medical costs of physician and psychologist visits
and lab tests were obtained from medical ofﬁces in the
Connecticut area. Cost of ﬂuoxetine and the herb were
based on 2002 published data. The cost per successfully
treated patient was evaluated for both therapies. One-
way and multi-way sensitivity analyses were performed
to determine the robustness of the data. RESULTS: The
base case analysis yielded a cost-effectiveness ratio of
$1788 per successful treatment with St. John’s Wort com-
pared to $2043 per successful treatment with ﬂuoxetine.
The results remained relatively robust to ﬂuctuations in
values of all variables. However, cost of therapy proved
to be an important determinant in overall cost-
effectiveness. At a cost of $20.00 per month, ﬂuoxetine
becomes the more cost-effective agent when St. John’s
Wort remains above $16.00 per month. CONCLU-
SIONS: St. John’s Wort is a viable option for patients with
mild to moderate depression in terms of both efﬁcacy and
cost. Consideration should be given for addition to third
party payers’ formularies.
